Immatics To Go Public Through Merger With ‘Blank Check’ Company Arya

 
• By Joseph Haas

German TCR developer in partnerships with GSK and BMS will go public and receive $252m at closing in a reverse merger-type transaction with Arya.

T Cell lymphocyte with receptors for cancer cell immunotherapy research 3D render
Immatics now will have a public listing and plenty of cash to advance its TCR pipeline

More from Deals

More from Business